|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Laboratory Medicine, Yamanashi
Medical University, Nakakoma, Japan; the Department of Biomembrane and
Biofunctional Chemistry, Graduate School of Pharmaceutical Sciences,
Hokkaido University, Sapporo, Japan; and the Department of
Physiology, University of Tennessee Health Science Center, Memphis,
TN.
The serum-borne lysophospholipid mediators sphingosine 1-phosphate
(Sph-1-P) and lysophosphatidic acid (LPA) have been shown to be
released from activated platelets and to act on endothelial cells. In
this study, we employed the repeated lipid extraction (under alkaline
and acidic conditions), capable of detecting Sph-1-P, LPA, and possibly
structurally similar lysophospholipids, whereby a marked formation of
[32P]Sph-1-P, but not [32P]LPA, was
observed in [32P]orthophosphate-labeled platelets.
Platelet Sph-1-P release, possibly mediated by protein kinase C, was
greatly enhanced in the presence of albumin, which formed a complex
with Sph-1-P. This finding suggests that platelet Sph-1-P may become
accessible to depletion by albumin when its transbilayer movement
(flipping) across the plasma membrane is enhanced by protein kinase C. Although human umbilical vein endothelial cells expressed receptors for both Sph-1-P and LPA, Sph-1-P acted much more potently than LPA on the
cells in terms of intracellular Ca++ mobilization,
cytoskeletal reorganization, and migration. The results suggest that
Sph-1-P, rather than LPA, is a major bioactive lysophospholipid that is
released from platelets and interacts with endothelial cells, under the
conditions in which critical platelet-endothelial interactions
(including thrombosis, angiogenesis, and atherosclerosis) occur.
Furthermore, albumin-bound Sph-1-P may account for at least some of the
serum biological activities on endothelial cells, which have been
ascribed to the effects of albumin-bound LPA, based on the similarities
between LPA and serum effects.
(Blood. 2000;96:3431-3438) Lysophosphatidic acid (LPA)1-3 and
sphingosine 1-phosphate (Sph-1-P)4-6 are now regarded as
serum-borne lipid mediators that exert potent and pleiotropic
biological effects. Although LPA and Sph-1-P are glycerolipid and
sphingolipid metabolite, respectively, they resemble each other in
structure as lysophospholipids.7 Furthermore, striking
similarities between LPA and Sph-1-P actions have been reported,
examples of which include platelet aggregation,8-10 mitogenesis,1,5,11,12 and cytoskeletal
remodeling.1,13-15 Such extracellular mediator activities
of LPA and Sph-1-P are mainly mediated by subfamilies of G
protein-coupled receptors, of which the most completely characterized
are those encoded by the endothelial differentiation genes
(edgs).16-18
Previously, we showed that in platelets Sph-1-P is rapidly formed from
sphingosine (Sph) by the action of Sph kinase, abundantly stored
intracellularly, and released into the extracellular environment on
stimulation.8,9 Furthermore, we subsequently showed that Sph-1-P acts as an endothelial cell survival factor; this bioactive lipid prevents apoptosis induced by withdrawal of growth factors and
stimulates DNA synthesis in human umbilical vein endothelial cells
(HUVECs).19 Recently, Sph-1-P was defined as a novel
regulator of angiogenesis.20 Accordingly, Sph-1-P should
be added to the list of platelet-derived mediators interacting with
endothelial cells. In addition, LPA is reported to be a bioactive lipid
released from activated platelets1-3,21 and to interact
with endothelial cells.22-24 Therefore, we, in this study,
examined the relative involvement of these bioactive lipids in
platelet-endothelial cell interactions.
Materials
The following materials were obtained from the indicated suppliers:
Sph-1-P and C6-ceramide (Cer) (Biomol, Plymouth Meeting, PA); LPA, phosphatidic acid (PA), Sph,
12-O-tetradecanoylphorbol 13-acetate (TPA), sphingomyelin,
bovine serum albumin (BSA; essentially fatty acid-free), trypan blue,
and FITC-conjugated phalloidin (Sigma, St Louis, MO); thrombin (Mochida
Pharmaceutical, Tokyo, Japan); collagen (Hormon-Chemie, Munich,
Germany); staurosporine (Kyowa Medex, Tokyo, Japan); recombinant human
basic fibroblast growth factor (bFGF) (Becton Dickinson Labware,
Lincoln Park, NJ); fetal calf serum (FCS) (ICN Biomedicals, Aurora,
OH); fura2-AM (Dojindo Laboratories, Kumamoto, Japan);
anti-paxillin monoclonal antibody (MoAb) (Transduction Laboratories,
Lexington, KY); the reconstituted basement membrane matrix Matrigel
(Becton Dickinson Labware, Bedford, MA); [ Cell preparation
HUVECs were isolated from human umbilical cords with trypsin treatment, plated onto 0.2% gelatin-coated dishes, and cultured in Dulbecco modified Eagle medium with 20% FCS, 10 ng/mL of bFGF, penicillin G (100 U/mL), and streptomycin sulfate (100 µg/mL) at 37°C under an atmosphere of 5% CO2 and 95% air. HUVECs were used between the third and the sixth passages. Platelet labeling with [32P]orthophosphate Platelets suspended in the HEPES buffer without added NaH2PO4 at a cell density of 1 × 109/mL were incubated with 5 mCi/mL of carrier-free [32P]orthophosphate for 2 hours at 37°C. Then, the platelets were diluted, washed twice, and finally adjusted to 3 × 108/mL. The [32P]orthophosphate-labeled platelets were stimulated, as indicated, under continuous shaking at 80 bpm.Under these conditions, platelet phosphatidylinositol, phosphatidylinositol 4-phosphate, phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate were heavily labeled with [32P] (data not shown), as we previously described.26 Lipid extraction and analysis Lipids were extracted from 0.5-mL aliquots of the HEPES buffer, including the indicated radiolabeled lipid or [32P]orthophosphate-labeled platelets. Three milliliters of ice-cold chloroform/methanol (1:2) was added to the samples, followed by thorough mixing and sonication. Phases were separated by adding 2 mL of chloroform and 2 mL of 1 mol/L KCl, without or with further addition of 80 µL of 7N NH4OH or 40 µL of concentrated HCl. The lower chloroform phases were evaporated under N2 and assayed for radiolabeled lipids. When indicated, the alkaline upper phases (after the addition of NH4OH) were transferred to new tubes, to which 3 mL of chloroform and 160 µL of concentrated HCl were added. The final lower chloroform phases, formed under the new acidic conditions, were then evaporated and assayed for radiolabeled lipids. All the lower phase samples were subject to liquid scintillation counting or to thin-layer chromatography (TLC) autoradiography as previously described.8 The TLC plates (silica gel 60 HPTLC plates; Merck, Darmstadt, Germany) were developed in butanol/acetic acid/water (3:1:1), and autoradiography was performed with Konica Medical Film (Konica, Tokyo, Japan) at 80°C. When
[3H]- or [14C]-labeled lipids were
analyzed, enhancer (EN3HANCE Spray, NEN Life Science
Products) treatment of TLC plates were performed.
[3H]Sph-1-P release from platelets labeled with [3H]Sph Platelet suspensions (0.5 mL), without or with inclusion of 1% BSA, were incubated with 1 µmol/L [3H]Sph (0.2 µCi) and stimulated at 37°C with the indicated agent. At the times indicated, the platelets were centrifuged for 15 seconds at 12 000g. Lipids were then extracted from the resultant medium supernatant and cell pellet and analyzed for [3H]Sph metabolism by TLC autoradiography, as described above. For quantitative analysis, silica gel areas that contained radiolabeled Sph-1-P were scraped off and counted by liquid scintillation counting. The percentage of Sph-1-P release into the medium was calculated as 100 × ([3H]Sph-1-P in medium) / (total [3H]Sph-1-P in medium plus cell pellets), and stimulus-dependent Sph-1-P release as (percentage of Sph-1-P release into the medium on stimulation) (percentage of
Sph-1-P release into the medium without stimulation).
Gel-filtration chromatography of [32P]Sph-1-P/BSA mixtures Sph-1-P, containing trace amounts of [3H]Sph-1-P, was incubated for 30 minutes with equimolar amounts of intact BSA or BSA denatured by boiling. The [3H]Sph-1-P/BSA mixtures were fractionated in a Sephadex G-25M (Pharmacia LKB Biotechnology AB, Uppsala, Sweden) gel-filtration column, which was equilibrated and run in a phosphate-buffered saline (PBS). Fractions (1 mL) were collected and assayed for their [3H]Sph-1-P content and albumin concentration, which were determined by liquid-scintillation counting and dye binding,27 respectively.RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR) Total RNA was prepared from HUVECs with the total RNA isolation system (Isogen, Wako Pure Chemical Industries, Osaka, Japan), and the isolation of messenger RNA (mRNA) was performed with Oligotex-dT30 < Super > (Takara Biomedicals, Tokyo, Japan), according to the manufacturer's instructions. The isolated mRNA was reverse transcribed with the use of SuperScript Preamplification System (Gibco BRL, Life Technologies, Rockville, MD). Reverse transcribed complementary DNA was amplified in a Perkin-Elmer 9600R thermal cycler (The Perkin-Elmer, Norwalk, CT), using Gene Taq (rTaq DNA polymerase; Wako Pure Chemical Industries).Oligonucleotide primer pairs used for edg-1, -2, -3, and -4 were 5'-CCAGAAAGACGAAGGGGACAAC-3' (sense) and 5'-CAGCAGTCGAAGCCCAGAGATT-3' (antisense) for edg-128; 5'-CAGGACCCAATACTCGGAGA-3' (sense) and 5'-CTGTAGAGGGGTGCCATGTT-3' (antisense) for edg-2 (GenBank accession no. Y09 479); 5'-TGGTCATCTGCAGCTTCATC-3' (sense) and 5'-CGTCTTCTTGCCAGACATCA-3' (antisense) for edg-3 (GenBank accession no. X83 864); 5'-CCCAACCAACAGGACTGACT-3' (sense) and 5'-GAGCCCTTATCTCTCCCCAC-3' (antisense) for edg-4 (GenBank accession no. AF011 466). Amplification was conducted with 35 cycles of 1 minute at 94°C, 1 minute at 60°C, and 1 minute at 72°C. Absence of contaminating DNA was confirmed by control reactions with RNA that had not been reverse transcribed. No amplification products were detected without addition of the reverse transcriptase (data not shown). PCR products (5 µL) were resolved by electrophoresis in a 2% agarose gel in TBE buffer (90 mmol/L Tris-Borate, 2 mmol/L EDTA, pH 8.3) and stained with ethidium bromide. The PCR products were cut from gels, solubilized, and sequenced with Dye Terminator Cycle Sequencing FS Ready Reaction Kits (The Perkin-Elmer) and analyzed with the use of an ABI PRISM 310 Genetic Analyzer (The Perkin-Elmer), according to the supplied protocols. Measurement of the intracellular Ca++ concentration ([Ca ++]i) The [Ca++]i measurement was performed with the use of the Ca++-sensitive fluorophore fura2. Confluent HUVECs were harvested by trypsinization, and the cell pellet was suspended in the HEPES buffer, containing 3 µmol/L fura2-AM. After 1 hour at 37°C, cells were washed twice, resuspended in fresh buffer, and adjusted to 2 × 106/mL. Fluorescence measurements were made with the use of a FS100 (Kowa, Tokyo, Japan). The [Ca++]i values were determined from the ratio of fura2 fluorescence intensity at 340 and 380 nm excitation.29HUVEC cytoskeletal reorganization Formation of actin filaments was studied by visualization of filamentous actin with FITC-labeled phalloidin, and focal adhesion site assembly was examined by immunostaining of paxillin. HUVECs were serum-starved for 2 hours and then stimulated as indicated in serum-free conditions. The cells were fixed in 3% paraformaldehyde for 40 minutes, permeabilized in 0.2% Triton X-100 for 8 minutes, incubated with 2.5 µg/mL of anti-paxillin MoAb for 2 hours, and washed with PBS. The cells were subsequently incubated with FluoroLink Cy3-labeled goat anti-mouse immunoglobulin G (Amersham Pharmacia Biotech, Buckinghamshire, UK) for 1 hour and then with 5 µg/mL of FITC-conjugated phalloidin for 40 minutes. After washing 3 times with PBS, the cells were viewed on a BH2 microscope (Olympus, Tokyo, Japan), and photographed on Fujicolor super G400 film (Fujifilm, Tokyo, Japan).HUVEC migration HUVEC migration was assessed by the modified Boyden chamber assay, ie, in Transwell cell culture chambers (Costar, Cambridge, MA) basically as previously described.30 Polycarbonate filters with 8-µm pores were used to separate the upper and lower chamber and were coated with 500 µg/mL of Matrigel. The coated filters were washed by serum-free medium and dried immediately. Then, HUVECs were added to the upper compartment of the chamber at a density of 1 × 105/100 µL of medium containing 0.1% BSA and incubated at 37°C. HUVECs were allowed to migrate toward Sph-1-P or LPA in the lower chamber. After the reaction, the filters were removed, fixed, stained with trypan blue, and mounted on glass slides. After removal of nonmigrated cells by wiping with cotton swabs, cells that had migrated through the filter to the lower surface were counted manually under a microscope in 5 predetermined fields. Each experiment was conducted in triplicate, and the mean was calculated.Data presentation All experiments were performed at least 3 times. The results shown are from a single representative experiment or the mean ± SD (n = 3).
Efficient extraction of lysophospholipids by repeated phase separations Lipids are usually extracted into the lower chloroform phase after the phase separation; Sph, C6-Cer, sphingomyelin (Figure 1), and PA (data not shown) were recovered into the lower phase, irrespective of pH conditions. In contrast, the water-soluble lipids Sph-1-P and LPA were extracted into the upper aqueous phase, especially under alkaline conditions (Figure 1). However, these lysophospholipids were recovered into the lower phase under acidic conditions (Figure 1), which is possibly due to the elimination of polarity of the phosphate moiety. When lipid extraction was first performed under the alkaline conditions and the resultant upper aqueous phases were re-extracted under acidic conditions, more than 40% and 60% of Sph-1-P and LPA, respectively, were recovered in the final lower phase (Figure 2A). Under these conditions, both Sph-1-P and LPA were confirmed to be stable, and no degradation products were detected in the TLC autoradiography (Figure 2B). This procedure is an easy and efficient method for specific extraction of Sph-1-P, LPA, and possibly structurally related lysophospholipids; other lipids examined, including Sph, C6-Cer, and sphingomyelin, were not present at all in the final lower phase (Figure 2A).
Detection of [32P]Sph-1-P in [32P]orthophosphate-labeled platelets To detect Sph-1-P and LPA in intact platelets, the repeated extraction procedures described above were performed on [32P]orthophosphate-labeled platelets. When the lower chloroform phase was analyzed by TLC autoradiography after a single-phase separation (either in the alkaline or acidic condition), numerous [32P]-labeled lipids were detected (data not shown). However, when the final chloroform phases were analyzed after the repeated phase separations (under the alkaline and then acidic conditions), [32P]Sph-1-P was mainly detected with a clear resolution (Figure 3). This finding confirms that our extraction procedure is very useful for detection of Sph-1-P and possibly structurally related lysophospholipids. In agreement with our previous report that Sph-1-P is abundantly stored even in resting platelets,31,32 [32P]Sph-1-P was detected in unstimulated platelets (Figure 3). When Sph, the substrate of Sph kinase, was added to platelets, the radioactivity of [32P]Sph-1-P was greatly enhanced (Figure 3), as expected from the fact that platelets possess high activity of Sph kinase.8,9 Although Sph kinase activity has been reported to be stimulated with receptor-mediated agonists or protein kinase C activators in several cells,5,6,12 the Sph-1-P levels were not enhanced by treatment of platelets with the potent and physiological agonists thrombin and collagen (Figure 3).33
In contrast to [32P]Sph-1-P, [32P]LPA was
not detectable under these conditions (Figure 3); the production of
[32P]LPA seemed much less than that of
[32P]Sph-1-P. Under the conditions employed, marked
synthesis of PA was detected in stimulated platelets (Figure
4), confirming failure to detect any
PA-specific phospholipase A activity in human platelet lysates but
arguing against the existence of active PA-specific phospholipase
A2 in platelets.3,21,34
Albumin-dependent release of Sph-1-P from activated platelets Previously, we reported that platelet Sph-1-P can be released extracellularly on stimulation, which may be mediated by protein kinase C activation.9 In this study, we checked the Sph-1-P release from platelets in the absence and presence of albumin in the medium. In accordance with our previous results,9 [3H]Sph-1-P, formed from [3H]Sph in platelets, was released extracellularly on stimulation with thrombin or TPA (Figure 5); thrombin activates protein kinase C as a result of phosphoinositide turnover, whereas TPA directly activates this kinase as a substitute for diacylglycerol.33 Furthermore, this stimulated release was blocked by staurosporine, an inhibitor of protein kinases, including protein kinase C.35 It should be noted that the extracellular release of Sph-1-P into the medium was much higher in the presence of extracellular BSA than in its absence (Figure 5). We assume that albumin extracts Sph-1-P stored in the platelets, when Sph-1-P location inside the cells is shifted on protein kinase C activation. In fact, we confirmed that Sph-1-P co-elutes with BSA (but not with denatured BSA) when a mixture of [3H]Sph-1-P and BSA is applied to a gel-filtration column (Figure 6), as is the case with LPA.21
The above results indicate that Sph-1-P (as well as LPA) can bind to albumin, that Sph-1-P stored inside platelets become accessible to depletion by albumin on protein kinase C activation, and that Sph-1-P may be present in the plasma or serum in an albumin-bound form. Expression of mRNA transcripts for Sph-1-P and LPA receptors in HUVECs To examine the effects of bioactive substances released from platelets on the endothelial cells is important in terms of platelet-endothelial interactions. For this purpose, we first confirmed the expression of the lysophospholipid receptors edgs16-18 by RT-PCR. Edg-1 and -3 have been identified as receptors for Sph-1-P, whereas Edg-1, -2, and -4 have been identified as receptors for LPA.17,18,20,36 RNA from HUVECs was prepared and reverse transcribed, followed by PCR amplification of specific transcripts. As demonstrated in Figure 7, HUVECs were found to express mRNA transcripts for edg-1, -2, -3, and -4; the sequence of each PCR product was confirmed (data not shown).
Sph-1-P, but not LPA, exhibits potent effects on HUVEC intracellular Ca++ mobilization, cytoskeletal reorganization, and migration Finally, we examined the effects of Sph-1-P and LPA on functional responses of HUVECs, which express receptors for both lysophospholipids. One of the most well-established short-term cellular responses to Sph-1-P5,6,8,37 and LPA1,2,21 is intracellular Ca++ mobilization. As reported,20 Sph-1-P rapidly and potently induced the increase in [Ca++]i in HUVECs (Figure 8A) in a concentration-dependent manner (Figure 8B). Sph-1-P-induced Ca++ mobilization was not affected by the presence of BSA in the medium (data not shown). In contrast to Sph-1-P, the stimulatory effect of LPA on intracellular Ca++ mobilization was very weak (Figure 8).
Both Sph-1-P and LPA have been shown to cause cytoskeletal remodeling
in several cells.1,2,13-15 Formation of actin filaments was studied by visualization of filamentous actin with FITC-labeled phalloidin, and focal adhesion site assembly was examined by
immunostaining of paxillin in HUVECs. Sph-1-P was found to markedly
induce these cytoskeletal responses (Figure
9). Stimulation of HUVECs with LPA
reportedly leads to the formation of stress fibers,24 but the effect of LPA was apparently weaker than that of Sph-1-P (Figure 9).
Finally, the effect of Sph-1-P or LPA on migration of HUVECs was
examined. Sph-1-P, but not LPA, stimulated directional migration (chemotaxis) of HUVECs (Figure 10).
The results described above suggest that Sph-1-P, rather than LPA, functions as a potent HUVEC agonist.
In the present study, we have demonstrated that Sph-1-P, abundantly stored in platelets, is released on activation and forms a high-affinity complex with albumin, while retaining its strong biological activities on HUVECs (possibly through Edg receptors). LPA is structurally related to Sph-1-P and has been shown to be released from activated platelets1-3,21 and to act on endothelial cells.22-24 However, both LPA release from platelets and its actions on HUVECs were minor in comparison with Sph-1-P. [32P]Sph-1-P was mainly detected in [32P]orthophosphate-labeled platelets (both in resting and activated states) with the use of our detection system, which could possibly detect structurally similar lysophospholipids (other than Sph-1-P), if existing. Accordingly, Sph-1-P is by far the most important lysophospholipid produced in platelets, at least from a quantitative viewpoint. Furthermore, platelet Sph-1-P is released extracellularly on stimulation,8,9 although its mechanism remains to be solved. Because Sph-1-P stored in platelets becomes susceptible to depletion by BSA when platelet protein kinase C is activated, one possible explanation is that the route of Sph-1-P externalization is enhanced by transbilayer movement (flipping) across the plasma membrane, as a result of modifications in membrane physical properties (accompanying protein kinase C activation). Previously, it was demonstrated that the mdr2 P-glycoprotein may have an essential role in the secretion of phosphatidylcholine into bile38 and hypothesized that the P-glycoproteins may transport other phospholipids.39,40 With previous reports in mind that such transport is ATP dependent and that protein kinase C phosphorylates P-glycoprotein,39,41 we examined the effect of verapamil, an inhibitor of P-glycoprotein.40 This inhibitor, however, did not affect Sph-1-P release under the conditions in which the release was completely inhibited by staurosporine (data not shown). Although the precise mechanism for extracellular release of Sph-1-P that follows platelet activation is still unclear, utilization of albumin to extract outer leaflet Sph-1-P would be a useful tool to detect transbilayer movement of Sph-1-P and hence to analyze Sph-1-P release. The concentrations of LPA and Sph-1-P in the serum were estimated to be approximately 1 to 5 µmol/L21,42 and 0.5 µmol/L,32 respectively. Because they both have been shown to be released from activated platelets,8,9,21 much more formation of [32P]Sph-1-P than [32P]LPA in platelets labeled with [32P]orthophosphate and activated with potent agonists (such as thrombin and collagen) was unexpected. Although Sph-1-P is formed through the action of Sph kinase, which is abundantly expressed in platelets,8,9 the metabolic pathways as well as the enzymes responsible for LPA production are not well characterized. Although LPA has been postulated to be produced from platelets (possibly by hydrolysis of newly formed PA through the action of phospholipase A2),1,21,34 the production seems much less than that of Sph-1-P. Our present results support the previous idea that there may be another source(s) of LPA present in serum.3,34 One possible mechanism is LPA formation mediated through plasma lysophospholipase D, which selectively acts on lysophosphatidylcholine, the second most abundant phospholipid in the plasma.3,43,44 Blood cells other than platelets (eg, neutrophils45) may contribute to the LPA production. Another possibility is that activated platelets may release phospholipase(s), capable of acting on the substrate in plasma and producing LPA. In this context, worthy of notice is the report that LPA can be generated through secretory, cytokine-inducible phospholipase A2, acting on microvesicles shed from blood cells challenged with inflammatory stimuli.46 Recently, LPA was shown to be formed during mild oxidation of low-density lipoprotein (LDL) and to be the active compound in mildly oxidized LDL and minimally modified LDL.24 In a clinical study, elevated blood LPA levels were detected in gynecological cancer patients.47 These cancer cells are reportedly capable of producing LPA under certain conditions and are considered to be a potential source of elevated plasma LPA in vivo.48 Further studies are required to obtain a definite conclusion on LPA sources in the blood. Although Edg-1, an inducible G protein-coupled receptor from vascular endothelial cells, was originally found to be a high-affinity receptor for Sph-1-P,17,20 LPA was found to stimulate this receptor, although as a low-affinity agonist.36 In addition, HUVECs were found to express Edg-3 (a Sph-1-P receptor) and Edg-2 and -4 (LPA receptors).18,20 Accordingly, it is possible that Sph-1-P and LPA equally act on endothelial cells. Contrary to our expectations, however, Sph-1-P was found to act as a much more potent agonist than LPA for HUVECs in terms of Ca++ mobilization, cytoskeletal remodeling, and migration. Consistent with our results, stimulation of HUVEC proliferation, chemotaxis, and FAK tyrosine phosphorylation by Sph-1-P, but not by LPA, has been reported recently.49,50 At present, the reason for much weaker effects of LPA on HUVECs is not clear. It is established that LPA is an albumin-bound serum factor that elicits a variety of responses.51,52 Furthermore, many serum biological activities have been ascribed to the effects of albumin-bound LPA, based on the similarities between LPA and serum effects.1-3,11,13,15,21,22,53,54 Previously, it was reported that LPA as well as serum albumin does induce intracellular Ca++ mobilization in HUVECs and that the Ca++-releasing action of serum albumin may be attributed to LPA presence.22 However, because the concentrations of LPA used in this study were as high as 60 µmol/L22 and Sph-1-P is a much more potent Ca++ mobilizer than LPA, the reported action of serum albumin may be attributed to Sph-1-P (but not LPA). At least in some cases, albumin-bound Sph-1-P may also account for the biological activities of serum. To support this notion, invasion of T-lymphoma cells reportedly depends on the presence of serum, which can be replaced not only by LPA but also by Sph-1-P.15 Although LPA bound to albumin in FCS was considered to be a possible active principle that induced actin reorganization in serum-starved Swiss 3T3 fibroblasts,13 this cytoskeletal response was later mimicked by Sph-1-P in the same cells.14 In HEK293 cells specifically transfected with Sph-1-P (but not LPA) receptors, rounded cell morphology was induced in the presence of serum.55 Furthermore, muscarinic K+ current in atrial myocytes was strongly activated by Sph-1-P, which caused desensitization of a response to the serum phospholipid challenge,56 suggesting that the serum effect may be ascribed to Sph-1-P. In conclusion, Sph-1-P (but not LPA) seems to be a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells under the conditions in which critical platelet-endothelial interactions (such as thrombosis, angiogenesis, and atherosclerosis) occur. While this work was under consideration for publication, we found that, in the presence of extracellular Ca++, [32P]LPA can be clearly detected in [32P]orthophosphate-labeled platelets stimulated with thrombin; this had not been the case in the absence of added Ca++ (Figure 3). This result suggests that LPA may be formed extracellularly by the action of Ca++-requiring lipase(s). Even in the presence of extracellular Ca++, however, the radioactivities incorporated into [32P]LPA were less than 20% of those into [32P]Sph-1-P.
The authors thank Dr Nobuo Hisano for helpful discussions.
Submitted November 11, 1999; accepted July 6, 2000.
Supported in part by the Clinical Pathology Research Foundation of Japan, the Ryoichi Naito Foundation for Medical Research, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture, Japan.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Yutaka Yatomi, Department of Laboratory Medicine, Yamanashi Medical University, Nakakoma, Yamanashi 409-3898, Japan; e-mail: yatomiy{at}res.yamanashi-med.ac.jp.
1.
Moolenaar WH.
Lysophosphatidic acid, a multifunctional phospholipid messenger.
J Biol Chem.
1995;270:12949-12952 2. Nietgen GW, Durieux ME. Intercellular signaling by lysophosphatidate. Cell Adhes Commun. 1998;5:221-235[Medline] [Order article via Infotrieve]. 3. Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res. 1995;34:151-184[Medline] [Order article via Infotrieve].
4.
Igarashi Y.
Functional roles of sphingosine, sphingosine 1-phosphate, and methylsphingosines: in regard to membrane sphingolipid signaling pathways.
J Biochem.
1997;122:1080-1087 5. Spiegel S, Merrill AH Jr. Sphingolipid metabolism and cell growth regulation. FASEB J. 1996;10:1388-1397[Abstract]. 6. Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messengers. J Leukoc Biol. 1999;65:341-344[Abstract]. 7. Durieux ME, Lynch KR. Signalling properties of lysophosphatidic acid. Trends Pharmacol Sci. 1993;14:249-254[Medline] [Order article via Infotrieve].
8.
Yatomi Y, Ruan F, Hakomori S, Igarashi Y.
Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets.
Blood.
1995;86:193-202
9.
Yatomi Y, Yamamura S, Ruan F, Igarashi Y.
Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid.
J Biol Chem.
1997;272:5291-5297
10.
Benton AM, Gerrard JM, Michiel T, Kindom SE.
Are lysophosphatidic acids or phosphatidic acids involved in stimulus activation coupling in platelets?
Blood.
1982;60:642-649 11. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell. 1989;59:45-54[Medline] [Order article via Infotrieve]. 12. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993;365:557-560[Medline] [Order article via Infotrieve]. 13. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-399[Medline] [Order article via Infotrieve]. 14. Wang F, Nobes CD, Hall A, Spiegel S. Sphingosine 1-phosphate stimulates rho-mediated tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 fibroblasts. Biochem J. 1997;324:481-488. 15. Stam JC, Michiels F, van der Kammen RA, Moolenaar WH, Collard JG. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J. 1998;17:4066-4074[Medline] [Order article via Infotrieve].
16.
Hla T, Maciag T.
An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors.
J Biol Chem.
1990;265:9308-9313
17.
Lee MJ, Van Brocklyn JR, Thangada S, et al.
Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1.
Science.
1998;279:1552-1555
18.
Goetzl E, An S.
Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate.
FASEB J.
1998;12:1589-1598
19.
Hisano N, Yatomi Y, Satoh K, et al.
Induction and suppression of endothelial cell apoptosis by sphingolipids: a possible in vitro model for cell-cell interactions between platelets and endothelial cells.
Blood.
1999;93:4293-4299 20. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301-312[Medline] [Order article via Infotrieve]. 21. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291:677-680.
22.
Fuentes E, Nadal A, Jacob R, McNaughton P.
Actions of serum and plasma albumin on intracellular Ca2+ in human endothelial cells.
J Physiol.
1997;504:315-326
23.
Alexander JS, Patton W, Christman BW, Cuiper LL, Haselton FR.
Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro.
Am J Physiol.
1998;274:H115-122
24.
Siess W, Zangl KJ, Essler M, et al.
Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.
Proc Natl Acad Sci U S A.
1999;96:6931-6936 25. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y. N, N-Dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry. 1996;35:626-633[Medline] [Order article via Infotrieve]. 26. Yatomi Y, Ozaki Y, Kume S. Synthesis of phosphatidylinositol 3,4-bisphosphate but not phosphatidylinositol 3,4,5-trisphosphate is closely correlated with protein-tyrosine phosphorylation in thrombin-activated human platelets. Biochem Biophys Res Commun. 1992;186:1480-1486[Medline] [Order article via Infotrieve]. 27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254[Medline] [Order article via Infotrieve]. 28. Takada Y, Kato C, Kondo S, Korenaga R, Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun. 1997;240:737-741[Medline] [Order article via Infotrieve].
29.
Grynkiewicz G, Poenie M, Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
J Biol Chem.
1985;260:3440-3450
30.
McCarthy JB, Palm SL, Furcht LT.
Migration by haptotaxis of a Schwann cell tumor line to the basement membrane glycoprotein laminin.
J Cell Biol.
1983;97:772-777 31. Yatomi Y, Ruan F, Ohta H, Welch RJ, Hakomori S, Igarashi Y. Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride. Anal Biochem. 1995;230:315-320[Medline] [Order article via Infotrieve].
32.
Yatomi Y, Igarashi Y, Yang L, et al.
Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum.
J Biochem.
1997;121:969-973
33.
Siess W.
Molecular mechanisms of platelet activation.
Physiol Rev.
1989;69:58-178 34. Gaits F, Fourcade O, Le Balle F, et al. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett. 1997;410:54-58[Medline] [Order article via Infotrieve]. 35. Tamaoki T. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol. 1991;201:340-347[Medline] [Order article via Infotrieve].
36.
Lee MJ, Thangada S, Liu C, Thompson BD, Hla T.
Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist.
J Biol Chem.
1998;273:22105-22112
37.
Okamoto H, Takuwa N, Gonda K, et al.
EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition.
J Biol Chem.
1998;273:27104-27110 38. Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451-462[Medline] [Order article via Infotrieve]. 39. Higgins CF. Flip-flop: the transmembrane translocation of lipids. Cell. 1994;79:393-395[Medline] [Order article via Infotrieve]. 40. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994;77:1071-1081[Medline] [Order article via Infotrieve].
41.
Chambers TC, McAvoy EM, Jacobs JW, Eilon G.
Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells.
J Biol Chem.
1990;265:7679-7686 42. Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids. 1999;34:17-21[Medline] [Order article via Infotrieve]. 43. Tokumura A, Nishioka Y, Yoshimoto O, Shinomiya J, Fukuzawa K. Substrate specificity of lysophospholipase D which produces bioactive lysophosphatidic acids in rat plasma. Biochim Biophys Acta. 1999;1437:235-245[Medline] [Order article via Infotrieve].
44.
Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K.
Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients.
Biol Reprod.
1999;61:195-199 45. Ito Y, Ponnappan U, Lipschitz DA. Excess formation of lysophosphatidic acid with age inhibits myristic acid-induced superoxide anion generation in intact human neutrophils. FEBS Lett. 1996;394:149-152[Medline] [Order article via Infotrieve]. 46. Fourcade O, Simon MF, Viode C, et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 1995;80:919-927[Medline] [Order article via Infotrieve].
47.
Xu Y, Shen Z, Wiper D, et al.
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
JAMA.
1998;280:719-723 48. Shen Z, Belinson J, Morton R, Xu Y, Xu Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol. 1998;71:364-368[Medline] [Order article via Infotrieve].
49.
Wang F, Van Brocklyn JR, Hobson JP, et al.
Sphingosine 1-phosphate stimulates cell migration through a Gi-coupled cell surface receptor: potential involvement in angiogenesis.
J Biol Chem.
1999;274:35343-35350 50. Lee OH, Lee DJ, Kim YM, et al. Sphingosine 1-phosphate stimulates tyrosine phosphorylation of focal adhesion kinase and chemotactic motility of endothelial cells via the Gi protein-linked phospholipase C pathway. Biochem Biophys Res Commun. 2000;268:47-53[Medline] [Order article via Infotrieve].
51.
Tigyi G, Dyer D, Matute C, Miledi R.
A serum factor that activates the phosphatidylinositol phosphate signaling system in Xenopus oocytes.
Proc Natl Acad Sci U S A.
1990;87:1521-1525
52.
Tigyi G, Miledi R.
Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells.
J Biol Chem.
1992;267:21360-21367 53. Koh JS, Lieberthal W, Heydrick S, Levine JS. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J Clin Invest. 1998;102:716-727[Medline] [Order article via Infotrieve]. 54. Postma FR, Jalink K, Hengeveld T, et al. Serum-induced membrane depolarization in quiescent fibroblasts: activation of a chloride conductance through the G protein-coupled LPA receptor. EMBO J. 1996;15:63-72[Medline] [Order article via Infotrieve].
55.
Van Brocklyn JR, Tu Z, Edsall LC, Schmidt RR, Spiegel S.
Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218.
J Biol Chem.
1999;274:4626-4632
56.
Bunemann M, Brandts B, zu Heringdorf DM, van Koppen CJ, Jakobs KH, Pott L.
Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate.
J Physiol.
1995;489:701-707
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  N. Kobayashi, N. Kobayashi, A. Yamaguchi, and T. Nishi Characterization of the ATP-dependent Sphingosine 1-Phosphate Transporter in Rat Erythrocytes J. Biol. Chem., August 7, 2009; 284(32): 21192 - 21200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gossens, S. Naus, S. Y. Corbel, S. Lin, F. M.V. Rossi, J. Kast, and H. J. Ziltener Thymic progenitor homing and lymphocyte homeostasis are linked via S1P-controlled expression of thymic P-selectin/CCL25 J. Exp. Med., April 13, 2009; 206(4): 761 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Bozza, A. M. Shah, A. S. Weyrich, and G. A. Zimmerman Amicus or Adversary: Platelets in Lung Biology, Acute Injury, and Inflammation Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 123 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Su, E. A. Mendoza, H.-i. Kwak, and K. J. Bayless Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1215 - C1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hosogaya, Y. Yatomi, K. Nakamura, R. Ohkawa, S. Okubo, H. Yokota, M. Ohta, H. Yamazaki, T. Koike, and Y. Ozaki Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity Ann Clin Biochem, July 1, 2008; 45(4): 364 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Park, C. Will, B. Martin, L. Gullotti, N. Friedrichs, R. Buettner, H. Schneider, S. Ludwig, and V. Wixler Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins FASEB J, July 1, 2008; 22(7): 2508 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Wixler, S. Hirner, J. M. Muller, L. Gullotti, C. Will, J. Kirfel, T. Gunther, H. Schneider, A. Bosserhoff, H. Schorle, et al. Deficiency in the LIM-only protein Fhl2 impairs skin wound healing J. Cell Biol., April 9, 2007; 177(1): 163 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D. Jung, J. S. Lee, Y. J. Kim, Y.-I. Jeong, C.-M. Lee, T. Baumruker, A. Billlich, Y. Banno, M. G. Lee, S.-C. Ahn, et al. Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of immunostimulatory activity in murine bone marrow-derived dendritic cells Int. Immunol., April 1, 2007; 19(4): 411 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wojciak-Stothard, L. Y. F. Tsang, E. Paleolog, S. M. Hall, and S. G. Haworth Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1173 - L1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kobayashi, T. Nishi, T. Hirata, A. Kihara, T. Sano, Y. Igarashi, and A. Yamaguchi Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner J. Lipid Res., March 1, 2006; 47(3): 614 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mehta and A. B. Malik Signaling Mechanisms Regulating Endothelial Permeability Physiol Rev, January 1, 2006; 86(1): 279 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sano, A. Kihara, F. Kurotsu, S. Iwaki, and Y. Igarashi Regulation of the Sphingoid Long-chain Base Kinase Lcb4p by Ergosterol and Heme: STUDIES IN PHYTOSPHINGOSINE-RESISTANT MUTANTS J. Biol. Chem., November 4, 2005; 280(44): 36674 - 36682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Aoki, Y. Yatomi, M. Ohta, M. Osada, F. Kazama, K. Satoh, K. Nakahara, and Y. Ozaki Sphingosine 1-Phosphate-Related Metabolism in the Blood Vessel J. Biochem., July 1, 2005; 138(1): 47 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Limaye, X. Li, C. Hahn, P. Xia, M. C. Berndt, M. A. Vadas, and J. R. Gamble Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members Blood, April 15, 2005; 105(8): 3169 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Summers and D. H. Nelson A Role for Sphingolipids in Producing the Common Features of Type 2 Diabetes, Metabolic Syndrome X, and Cushing's Syndrome Diabetes, March 1, 2005; 54(3): 591 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Krump-Konvalinkova, S. Yasuda, T. Rubic, N. Makarova, J. Mages, W. Erl, C. Vosseler, C. J. Kirkpatrick, G. Tigyi, and W. Siess Stable Knock-Down of the Sphingosine 1-Phosphate Receptor S1P1 Influences Multiple Functions of Human Endothelial Cells Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 546 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yatomi, S. Yamamura, N. Hisano, K. Nakahara, Y. Igarashi, and Y. Ozaki Sphingosine 1-Phosphate Breakdown in Platelets J. Biochem., October 1, 2004; 136(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Roviezzo, F. Del Galdo, G. Abbate, M. Bucci, B. D'Agostino, E. Antunes, G. De Dominicis, L. Parente, F. Rossi, G. Cirino, et al. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate PNAS, July 27, 2004; 101(30): 11170 - 11175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou and K. S. Murthy Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2 Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1130 - C1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Deguchi, S. Yegneswaran, and J. H. Griffin Sphingolipids as Bioactive Regulators of Thrombin Generation J. Biol. Chem., March 26, 2004; 279(13): 12036 - 12042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takeya, E. C. Gabazza, S. Aoki, H. Ueno, and K. Suzuki Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells Blood, September 1, 2003; 102(5): 1693 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Kim, E. J. Jo, H.-Y. Lee, M. S. Cha, J. K. Min, C. H. Choi, Y. M. Lee, Y.-A. Choi, S.-H. Baek, S. H. Ryu, et al. Sphingosine 1-Phosphate in Amniotic Fluid Modulates Cyclooxygenase-2 Expression in Human Amnion-derived WISH Cells J. Biol. Chem., August 22, 2003; 278(34): 31731 - 31736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Schaphorst, E. Chiang, K. N. Jacobs, A. Zaiman, V. Natarajan, F. Wigley, and J. G. N. Garcia Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L258 - L267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jin, E. Knudsen, L. Wang, Y. Bryceson, B. Damaj, S. Gessani, and A. A. Maghazachi Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation Blood, June 15, 2003; 101(12): 4909 - 4915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sano, D. Baker, T. Virag, A. Wada, Y. Yatomi, T. Kobayashi, Y. Igarashi, and G. Tigyi Multiple Mechanisms Linked to Platelet Activation Result in Lysophosphatidic Acid and Sphingosine 1-Phosphate Generation in Blood J. Biol. Chem., June 7, 2002; 277(24): 21197 - 21206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lum Lysophospholipids in the regulation of endothelial barrier function Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1335 - L1336. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tosaka, F. Okajima, Y. Hashiba, N. Saito, T. Nagano, T. Watanabe, T. Kimura, and T. Sasaki Sphingosine 1-Phosphate Contracts Canine Basilar Arteries In Vitro and In Vivo: Possible Role in Pathogenesis of Cerebral Vasospasm Stroke, December 1, 2001; 32(12): 2913 - 2919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Levade, N. Auge, R. J. Veldman, O. Cuvillier, A. Negre-Salvayre, and R. Salvayre Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology Circ. Res., November 23, 2001; 89(11): 957 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Abnet, C. B. Borkowf, Y.-L. Qiao, P. S. Albert, E. Wang, A. H. Merrill Jr., S. D. Mark, Z.-W. Dong, P. R. Taylor, and S. M. Dawsey A Cross-Sectional Study of Human Serum Sphingolipids, Diet and Physiologic Parameters J. Nutr., October 1, 2001; 131(10): 2748 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Kluk and T. Hla Role of the Sphingosine 1-Phosphate Receptor EDG-1 in Vascular Smooth Muscle Cell Proliferation and Migration Circ. Res., September 14, 2001; 89(6): 496 - 502. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-32P]ATP- and ATP-dependent
phosphorylation of Sph and [3-3H]Sph, respectively, which
were both catalyzed by Sph kinase obtained from human
platelets.
) or with further addition of NH4OH
(
) or HCl (
). The phases were then separated, and radioactivities
of the lower phase were counted by liquid scintillation counting. The
percentage of recovery of each radiolabeled lipid into the lower
chloroform phase was calculated as 100 × the radioactivity in the
lower chloroform phase/the radioactivity added.
) or LPA (
), and the increases in
[Ca++]i (the ratio of fura2 fluorescence)
were measured.
